Karyopharm Therapeutics Inc., a clinical pharmaceutical company, reported first-line positive results from the STORM phase 2b study that evaluated the effect of selinexor in heavily pre-treated patients with refractory multiple myeloma. Regarding the primary objective of the STORM study, oral selinexor achieved a global response rate (ORR) of 25.4%, which included two complete (CR) and 29 partial (PR) responses or very good partial responses (VGPR) in these patients with refractory myeloma. The median duration of the response (DOR), a key secondary objective, was 4.4 months. All responses were confirmed by an independent review committee (IRC). Selinexor recently obtained the Fast-Track designation by the US Food and Drug Administration (FDA) for this indication.